(PharmaNewsWire.Com, March 19, 2021 ) The report "Hemodynamic Monitoring Systems Market by Product (Disposables and Monitors), Type (Invasive, Minimally Invasive, and Non-invasive), End User (Hospitals, Clinics & Ambulatory Care Center, and Home Care Setting), and Region - Global Forecasts to 2023", The global Hemodynamic Monitoring Systems Market is expected to reach USD 1,167.4 million by 2023 from USD 857.8 million in 2018, at a CAGR of 6.4% during the forecast period. The key factors driving the growth of this market are technological advancements in hemodynamic monitoring systems, increasing research into hemodynamic monitoring systems, influx of VC funding, rising prevalence of cardiovascular diseases & diabetes, rising geriatric population & growing number of surgeries, awareness initiatives by industry players, and government focus on critical care infrastructure & services.
Browse 91 market data Tables and 36 Figures spread through 149 Pages and in-depth TOC on "Hemodynamic Monitoring Systems Market - Global Forecasts to 2023"
By product, the disposables segment is expected to account for the largest share of the market in 2018
On the basis of product, the global market is segmented into two broad categories monitors and disposables. In 2018, the disposables segment is expected to account for the largest share of the hemodynamic monitoring systems market owing to the presence of a large patient population undergoing diagnosis for vascular diseases; increasing adoption of disposables among medical professionals owing to their procedural and technological benefits; and ongoing technological advancements in catheters, probes, sensors, and guidewires. Furthermore, the rising incidence of risk factors for vascular diseases (such as obesity, hypertension, alcoholism, and diabetes) is also expected to support the growth of this market segment during the forecast period.
By type, the invasive systems segment is expected to account for the largest share of the market in 2018
On the basis of type, the hemodynamic monitoring systems market is segmented into invasive, minimally invasive, and noninvasive systems. In 2018, the invasive systems segment is expected to account for the largest share of the global market. Invasive hemodynamic monitoring provides accurate, continuous, and comprehensive data on the hemodynamic state of a patient.
By end user, the hospitals segment is expected to account for the largest share of the market in 2018
On the basis of end user, the hemodynamic monitoring systems market is segmented into hospitals, clinics and ambulatory care centers (ACCs), and home care settings. In 2018, hospitals segment is expected to account for the largest share of the global market. The large share of this segment can be attributed to the presence of big cath labs in hospitals, successful application of hemodynamic monitoring systems in several procedures, global increase in the number of patients and the subsequent increase in the prevalence of cardiovascular and other chronic diseases, and continuous technological advancements coupled with government funding.
In 2018, North America is expected to account for the largest share of the hemodynamic monitoring systems market, followed by Europe. Factors such as rising geriatric population, increasing prevalence of diabetes and hypertension, availability of technologically advanced hemodynamic monitoring systems, growing use of patient monitoring systems, and a large base of major device manufacturers in the US and Canada are contributing to the large share of North America.
The key players in the global hemodynamic monitoring systems market are Edwards Lifesciences Corporation (US), PULSION Medical Systems SE (Germany), LiDCO Group plc (UK), Cheetah Medical (Israel), Deltex Medical Group Plc. (UK), ICU Medical (US), Osypka Medical GmbH (Germany), CareTaker Medical (US), CNSystems (Austria), NI Medical (Israel), and Uscom (Australia).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
